Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30967467 | 0.87 | NPC1 (0.56) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL11545921 | 0.86 | NPC1 (0.68) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL11544509 | 0.86 | NPC1 (0.53) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL11545932 | 0.85 | NPC1 (0.61) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL11545573 | 0.85 | NPC1 (0.61) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL248876 | 0.84 | NPC1 (0.53) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL13498219 | 0.83 | NPC1 (0.50) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL5799758 | 0.83 | ALDH1A1 (0.54) | ALDH1A1LMNAMAPTKMT2AMEN1 | |
| SCHEMBL214555 | 0.83 | NPC1 (0.58) | ALDH1A1LMNAMAPTKMT2ARECQL | |
| SCHEMBL30159613 | 0.82 | ALDH1A1 (0.79) | ALDH1A1LMNAMAPTKMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100456398-C | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORP (JP) | 2009-01-28 | — | — | CN | claimed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | claimed |
| CN-117384140-B | Benzimidazole derivative and application thereof | 沈阳药科大学 | 2024-10-11 | — | — | CN | disclosed |
| CN-117384140-A | Benzimidazole derivative and application thereof | 沈阳药科大学 | 2024-01-12 | — | — | CN | disclosed |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | PELOTON THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2017-03-30 | — | — | US | disclosed |
| WO-2015175845-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | PELOTON THERAPEUTICS, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2011-03-03 | — | — | US | disclosed |
| EP-2276750-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | Auckland Uniservices Limited (NZ) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009120094-A2 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-10-01 | — | — | WO | disclosed |
| CN-100456398-C | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | RUBYCON CORP (JP) | 2009-01-28 | — | — | CN | disclosed |
| CN-1529892-A | Electrolyte for driving electrolytic capacitor and electrolytic capacitor | 如碧空株式会社 | 2004-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088523-A1 | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF | ACSS2, GLS2, ACSL3 | ALDH1A1 176/4885LMNA 3141/4885MAPT 4860/4885 |
| US-20110053907-A1 | SUBSTITUTED PYRIMIDINES AND TRIAZINES AND THEIR USE IN CANCER THERAPY | PIK3CA, PIK3R5, PIK3CD | ALDH1A1 2617/4885LMNA 4096/4885MAPT 4526/4885 |
| US-10040767-B2 | Benzimidazole derivatives and uses thereof | ACSS2, GLS2, ACSL3 | ALDH1A1 176/4885LMNA 3141/4885MAPT 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.